Skip to main content

Central Nervous System Carcinoma clinical trials at UCSF

1 research study open to eligible people

Showing trials for
  • See if Memantine Protects the Brain During Radiation Therapy Treatment for Primary Central Nervous System Tumors

    open to eligible people ages 4-17

    This phase III trial compares memantine to usual treatment in treating patients with primary central nervous system tumors. Memantine may block receptors (parts of nerve cells) in the brain known to contribute to a decline in cognitive function. Giving memantine may make a difference in cognitive function (attention, memory, or other thought processes) in children and adolescents receiving brain radiation therapy to treat a primary central nervous system tumors.

    San Francisco, California and other locations

Our lead scientists for Central Nervous System Carcinoma research studies include .

Last updated: